Stockscreener 앱 받기
15.07
0.46%
-0.065
전일 마감가:
$15.14
열려 있는:
$15.12
하루 거래량:
358.29K
Relative Volume:
0.21
시가총액:
$47.43B
수익:
$30.25B
순이익/손실:
$1.37B
주가수익비율:
35.41
EPS:
0.4257
순현금흐름:
$5.08B
1주 성능:
-0.78%
1개월 성능:
+4.59%
6개월 성능:
+3.65%
1년 성능:
+8.50%
1일 변동 폭
$14.89
$15.12
1주일 범위
$14.89
$15.17
52주 변동 폭
$12.57
$15.30
다케다약품공업 ADR Stock (TAK) Company Profile
명칭
Takeda Pharmaceutical Co Adr
전화
-
주소
-
TAK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
15.07 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
ZTS
Zoetis Inc
|
164.31 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.19 | 17.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.82 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
다케다약품공업 ADR Stock (TAK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-03-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-07-19 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2021-10-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 개시 | Cowen | Market Perform |
| 2019-08-15 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
모두보기
다케다약품공업 ADR 주식(TAK)의 최신 뉴스
[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
PD Stock on the Rise: A Promising Investment - The InvestChronicle
TAK or DSNKY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Vital Energy Inc (VTLE) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
China Liberal Education Holdings Ltd: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Takeda Pharmaceutical Stock (NYSE: TAK): Strategic Focus on Oncology and Growth Opportunities - Value the Markets
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds - Seeking Alpha
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Charles Schwab Trying To Close In On Key Technical Measure - Inkl
Takeda Pharmaceutical Co ADR (TAK) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Takeda Pharmaceutical ADR Trying To Close In On Key Technical Measure - Inkl
XFOR: Receives €28.5 Upfront for Licensing Agreement with Norgine… - MSN
TAK vs. DSNKY: Which Stock Is the Better Value Option? - Nasdaq
Ex-Intern Becomes Billionaire in Australia Pharmacy Merger - MSN
Vyvanse Leaks: Beyond The Headlines - Truth or Fiction
IgA nephropathy Clinical Trials and Pipeline 2025: EMA, PDMA, - openPR
IgA nephropathy Clinical Trials and Pipeline Assessment: EMA, - openPR
Procter & Gamble Co (PG) expanding its growth trajectory ahead - SETE News
Prepare Yourself for Liftoff: AMKOR Technology Inc (AMKR) - SETE News
Takeda Pharmaceutical Co ADR [TAK] President, Plasma-Derived Ther makes an insider purchase of 19,073 shares worth 0.28 million. – Knox Daily - Knox Daily
Advanced Drainage Systems Inc [WMS] Records 50-Day SMA of $122.78 - Knox Daily
GFL Shares Experience Surge in Value - Knox Daily
UBS Group AG [UBS] Shares Rise 2.39 % on Thursday - Knox Daily
Takeda Pharmaceutical Co ADR (TAK)’s stock price range in the last year - US Post News
Inmode Ltd (INMD) Stock Price and Analyst Predictions - The News Heater
Recent Insider Activity Could Benefit Wabash National Corp (WNC) - Knox Daily
Analyzing Takeda Pharmaceutical Co ADR (TAK) After Recent Trading Activity - Knox Daily
Takeda signals 2025 growth with raised guidance, JPY 100B buyback, and new leadership transition - MSN
Ascentage Has First U.S. Biotech IPO of 2025, Raising $126M to Bring Its Cancer Meds to the World - Dealbreaker
Keros Therapeutics seals $200M deal with Takeda - Investing.com
Japan’s Takeda launches innovation centre in Bengaluru; to hire 750 in 2025 - Deccan Herald
Weekly Upgrades and Downgrades - InvestorPlace
Amgen stock price formed a death cross: will it rebound in 2025? - MSN
Takeda-backed Ascentage Pharma files for $100M IPO (IPO:NYSEARCA) - Seeking Alpha
다케다약품공업 ADR (TAK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.33%
0.59%
자본화:
|
볼륨(24시간):